In this study, the authors investigate the risk of type 2 diabetes mellitus (T2DM) over a wide range of body iron stores in a prospective cohort of more than 1,600 men in the Kuopio Ischemic Heart Disease Risk Factor study (aged 42–60 yrs), who were free of T2DM and hereditary haemochromatosis at baseline in 1984–1989.

Professor Michael Bohm at ESC 2012
Professor John Cleland at ESC 2012
Professor Alain Cohen-Solal at ESC 2012
Professor Dirk van Veldhuisen at ESC 2012

In 2012, the European Society of Cardiology (ESC) published updates to their Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. For the first time, the guidelines consider iron deficiency as a significant co-morbidity in its own right, independently of anaemia, reflecting the growing awareness of the condition as a significant barrier in the management of heart failure.

High dose intravenous ferric carboxymaltose does not alter levels of inflammatory and endothelial markers in patients with pre-dialysis chronic renal failure and iron deficiency anaemia, according to a new report. The study provides initial evidence addressing concerns regarding the pro-inflammatory properties of intravenous iron.

Iron-deficient cardiac patients treated with intravenous ferric carboxymaltose show significant improvements in a range of quality of life scores, according to a new analysis. Measures relating to physical impairment are particularly responsive to iron therapy, with improvements in ‘mobility’ and ‘usual activity’ likely to have significant impact upon patients’ everyday life.

Treatment for iron deficiency in patients with heart disease (of any type) is often complex, due to multiple co-morbidities and concomitant therapies. The ultimate aim is to restore healthy iron metabolism and turnover in patients with heart disease to improve morbidity, mortality and quality of life1.

Intravenous iron therapy


Subscribe to RSS - Cardiology